Dr. Anne Bassett heads the Clinical Genetics Research Program and is a Clinician Scientist in the Campbell Family Mental Health Research Institute at CAMH. She is also a Senior Scientist at the Toronto General Research Institute, holds the Dalglish Chair at the University Health Network, and is Professor of Psychiatry at the University of Toronto.
Areas of Research
Dr. Bassett is an internationally renowned expert in the genetics of schizophrenia and other complex developmental disorders, including congenital cardiac disease. She is the principal investigator of studies that aim to understand the genetic architecture of schizophrenia and characterize clinically relevant genetic subtypes of schizophrenia. The goal is to gain new insights into the mechanisms of the illness that will help develop new treatments. Dr. Bassett has pioneered studies of a molecular subtype of schizophrenia known as 22q11.2 deletion syndrome. Individuals born with a 22q11.2 deletion have a one in four chance of developing schizophrenia. About one out of every 100 patients with schizophrenia has a 22q11.2 deletion that may be found with a standard clinical blood test. Translating genetic research findings directly into clinical practice is an exciting area of her research that has a strong medical focus. Dr. Bassett's career also includes teaching at all levels and public service, including for the Schizophrenia Society of Canada.
View Dr. Bassett's publications on PubMed.